Last reviewed · How we verify

protease inhibitors

French National Agency for Research on AIDS and Viral Hepatitis · FDA-approved active Small molecule Under review Quality 0/100

protease inhibitors is a Protease inhibitor Small molecule drug developed by French National Agency for Research on AIDS and Viral Hepatitis. It is currently FDA-approved for HIV-1 infection (in combination antiretroviral therapy), HIV-1 treatment-experienced patients with protease inhibitor-resistant virus.

Protease inhibitors block the activity of viral proteases, preventing the cleavage of viral polyproteins necessary for viral replication and maturation.

Protease inhibitors are medications that interfere with enzymes that cleave proteins, and they are used to treat conditions such as HIV-1 Infection, AIDS, and Chronic Hepatitis B. They work by selectively binding to viral proteases and blocking proteolytic cleavage of protein precursors necessary for viral replication.

At a glance

Generic nameprotease inhibitors
SponsorFrench National Agency for Research on AIDS and Viral Hepatitis
Drug classProtease inhibitor
TargetHIV protease
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

Protease inhibitors are a class of antiretroviral drugs that bind to and inhibit HIV protease, an enzyme essential for processing viral proteins during HIV replication. By preventing protease activity, these drugs block the production of mature, infectious viral particles, thereby reducing viral load and slowing disease progression. They are typically used in combination antiretroviral therapy (cART) regimens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about protease inhibitors

What is protease inhibitors?

protease inhibitors is a Protease inhibitor drug developed by French National Agency for Research on AIDS and Viral Hepatitis, indicated for HIV-1 infection (in combination antiretroviral therapy), HIV-1 treatment-experienced patients with protease inhibitor-resistant virus.

How does protease inhibitors work?

Protease inhibitors block the activity of viral proteases, preventing the cleavage of viral polyproteins necessary for viral replication and maturation.

What is protease inhibitors used for?

protease inhibitors is indicated for HIV-1 infection (in combination antiretroviral therapy), HIV-1 treatment-experienced patients with protease inhibitor-resistant virus.

Who makes protease inhibitors?

protease inhibitors is developed and marketed by French National Agency for Research on AIDS and Viral Hepatitis (see full French National Agency for Research on AIDS and Viral Hepatitis pipeline at /company/french-national-agency-for-research-on-aids-and-viral-hepatitis).

What drug class is protease inhibitors in?

protease inhibitors belongs to the Protease inhibitor class. See all Protease inhibitor drugs at /class/protease-inhibitor.

What development phase is protease inhibitors in?

protease inhibitors is FDA-approved (marketed).

What are the side effects of protease inhibitors?

Common side effects of protease inhibitors include Gastrointestinal disturbances (nausea, diarrhea, abdominal pain), Lipid abnormalities (elevated cholesterol and triglycerides), Hyperglycemia / diabetes, Lipodystrophy (fat redistribution), Hepatotoxicity, Headache.

What does protease inhibitors target?

protease inhibitors targets HIV protease and is a Protease inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing